Concizumab Approval Marks a Major Step Forward in Hemophilia Management

On October 24, 2025, the Medicines and Healthcare products Regulatory Agency (MHRA) approved Concizumab (Alhemo) to prevent or reduce the frequency of bleeding episodes in people aged 12 years and older with haemophilia A or B with inhibitors.

Haemophilia is a rare hereditary condition where blood clotting is impaired due to a deficiency of clotting factors VIII (haemophilia A) or IX (haemophilia B). Concizumab works differently by blocking a natural anticoagulant protein called (tissue factor pathway inhibitor), which increases clotting activity and helps prevent bleeding.

Alhemo is administered as a daily subcutaneous injection. The MHRA will continue to monitor its safety and effectiveness closely. Healthcare professionals and patients are encouraged to report any suspected side effects to the MHRA Yellow Card scheme.

This approval was granted through the International Recognition Procedure, leveraging assessments from trusted global regulatory partners for the benefit of UK patients.

Learn more: Concizumab approved to prevent or reduce the frequency of bleeding episodes in people aged 12 years and older with haemophilia A or B with inhibitors